Hemodialysis arteriovenous fistulas: A nineteenth century view of a twenty first century problem

Journal of Vascular Access

Volumn 6, Issue 2, 2005, Pages 64-71

  Ross, Jamie L ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Arteriovenous fistulas; Hemodialysis; Stenosis; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; ANTITHROMBIN III; BLOOD CLOTTING FACTOR; CLOPIDOGREL; D DIMER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; FIBRINOGEN; FIBRINOPEPTIDE A; FISH OIL; IMMUNOSUPPRESSIVE AGENT; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; PROTEIN C; PROTEIN S;

ANGIOGRAPHY; ARTERIOVENOUS FISTULA; BLEEDING; BLOOD FLOW; BLOOD VESSEL INJURY; BLOOD VESSEL OCCLUSION; BRACHYTHERAPY; CARDIOLOGY; DRUG MECHANISM; ENZYME INHIBITION; HEALTH PROGRAM; HEMATOMA; HEMODIALYSIS; HUMAN; HYPOALBUMINEMIA; INFLAMMATION; KIDNEY FAILURE; MEDICAL LITERATURE; ONCOLOGY; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RADIOTHERAPY; RESTENOSIS; REVIEW; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOSIS; VASCULAR ACCESS; VASCULAR PATENCY; VASCULAR SURGERY;

EID: 22944464082     PISSN: 11297298     EISSN: None     Source Type: Journal    
DOI: 10.1177/112972980500600204     Document Type: Review

References (63)

1. Department of Health and Human Services Centers for Medicare and Medicaid Services. Adult in-center hemodialysis patients- vascular access. 2003 Annual Report ESRD Clinical Performance Measures Project 2003; 30.
2. Perra GB, Mueller MP, Kubaska SM, et al. Superiority of autogenous arteriovenous hemodialysis access: Maintenance of function with fewer secondary interventions. Ann Vasc Surg 2004; 18: 66-73.
3. Lee H, Manns B, Taub K, et al. Cost Analysis of Ongoing care of patients with end-stage renal disease: The impact of dialysis modality and dialysis access. Am J Kidney Dis 2002; 40: 611-22.
4. Beathard GA, Litchfield T. Functions of a dedicated vascular access facility promoting AVF use. Nephrol News Issues 2004; 11: 44-8.
5. Rayner HC, Pisoni RL, Gillespie BW, et al. Creation, cannulation and survival of arteriovenous fistulae: Data from the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2003; 63: 323-30.
6. Collins AJ, Roberts TL, Peter WL, et al. United States Renal Data System Assessment of the Impact of the National Kidney Foundation - Dialysis Outcomes Quality Initiative Guidelines. Am J Kidney Dis 2002; 39: 784-95.
7. Virchow R. Abhandlungen zur Wissenschafligen Medizzin. Von Medinger Sohn & Co. 1856.
8. Johnson C, Zhu YR, Matt C, et al. Prognostic value of intraoperative blood flow measurements in vascular access surgery. Surgery 1998; 124: 798.
9. Chandraratna PAN. Determination of contribution of arteriovenous fistula to total cardiac output by Doppler computer. Nephrol Dial Transplant 1984; 41: 251.
10. Iwashima Y, Horio T, Takami Y et al. Effects of the creation of arteriovenous fistula for hemodialysis on cardiac function and natriuretic peptide levels in CRF. Am J Kidney Dis 2002; 40: 974-82.
11. Casserly LF, Givertz MM. Congestive heart failure and its management in end-stage renal failure. In: Lo Scalzo G, London GM, eds. Cardiovascular disease in end-stage renal failure. New York: Oxford University Press 2000: 289-315.
12. Wedgewood KR, Wiggens PA, Guillou PJ. A prospective study of end to side versus side to side ateriovenous fistulas for hemodialysis. Br J Surg 1984; 71: 640.
13. Gordon IL, Arefi M. Physiology of the ateriovenous fistula. In: Wilson SE, ed. Vascular access principles and practice. St Louis: Mosby 2002: 33-47.
14. Feldman HI, Joffe M, Rosas SE, et al. Predictors of successful arteriovenous fistula maturation. Am J Kidney Dis 2003; 42: 1000-12.
15. Huber TS, Ozaki CK, Flynn TC, et al. Prospective validation of an algorithm to maximize native arteriovenous fistulae for chronic hemodialysis access. J Vasc Surg 2002; 36: 452-9.
16. Malovrh M. Native arteriovenous fistula: Preoperative evaluation. Am J Kidney Dis 2002; 39: 1218-25.
17. Malovrh M. Non-invasive evaluation of vessels by duplex sonography prior to construction of fistulas for hemodialysis. Nephrol Dial Transplant 1998; 13: 125-9.
18. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Vascular Access. Am J Kidney Dis 2001; 37: S137-81.
19. Chin AI, Chang W, Fitzgerald JT, et al. Intra-access blood flow in patients with newly created upper-arm arteriovenous native fistulae for hemodialysis access. Am J Kidney Dis 2004; 44: 850-8.
20. Sivanesan S, How T, Bakran A. Characterizing flow distributions in AV fistula for hemodialysis access. Nephrol Dial Transplant 1998; 13: 3108.
21. Beathard GA, Settle SM, Shields MW. Salvage of the nonfunctioning arteriovenous fistula. Am J Kidney Dis 1999; 33: 910-6.
22. Konings CJ, Dammers R, Rensma PL, et al. Arterial wall properties in patients with renal failure. Am J Kidney Dis 2002; 39: 1206-12.
23. Grobbee DE, Bots ML. Carotid artery intima-media thickness as an indicator of generalized atherosclerosis. J Intern Med 1994; 236: 567-73.
24. Kim YO, Song HC, Yang CW, et al. Preexisting intimal hyperplasia of the radial artery is associated with early failure of radiocephalic arteriovenous fistula in hemodialysis patients. Am J Kidney Dis 2003; 41: 422-8.
25. Wali MA. Smooth muscle changes in the cephalic vein of renal failure patients before use as an arteriovenous fistula. J Smooth Muscle Res 2002; 38: 75-85.
26. Remuzzi A. Radial artery wall shear stress evaluation in patients with arteriovenous fistula for hemodialysis access. Biorheology 2003; 40: 423-30.
27. Nath KA, Kanakiriya SK, Grande JP, et al. Increased venous proinflammatory gene expression and intimal hyperplasia in an aorto-caval fistula model in the rat. Am J Pathol 2003; 162: 2079-90.
28. Corpataux JM. Low-pressure environment and remodeling of the forearm vein in Brescia-Cimino hemodialysis access. Nephrol Dial Transplant 2002; 17: 1057-62.
29. Maya ID, Oser R, Saddekni S, et al. Vascular access stenosis: Comparison of arteriovenous grafts and fistulas. Am J Kidney Dis 2004; 44: 859-65.
30. Stracke S, Konner K, Kostlin I, et al. Increased espression of TGF-beta1 and IGF-I in inflammatory stenotic lesions of hemodialysis fistulas. Kidney Int 2002; 61: 1011-9.
31. Chang CJ, Ko PJ, Hsu LA, et al. Highly increased cell proliferation activity in the restenotic hemodialysis vascular access after percutaneous transluminal angioplasty: Implication in prevention of restenosis. Am J Kidney Dis 2004; 3: 74-84.
32. de Graaf R, Dammers R, Vainas T, et al. Dectection of cell-cycle regulators infailed arteriovenous fistulas in haemodialysis. Nephrol Dial Transplant 2003; 18: 814-8.
33. Sun S. Inhibitory effect of brachytherapy on intimal hyperplasia in arteriovenous fistula. J Surg Res 2003; 115: 200-8.
34. von Tongeren RB, Levendag PC, Coen VL, et al. External beam radiation therapy to prevent anastomotic intimal hyperplasia in prosthetic arteriovenous fistulas: results of a randomized trial. Radiother Oncol 2003; 69: 73-7.
35. Konner K, Nonnast-Daniel B, Ritz, E. The arteriovenous fistula. J Am Soc Nephrol 2003; 14: 1669-80.
36. Tomas S, Shinzato T, Fukui H, et al. A timesaving method to create a fixed puncture route for the buttonhole technique. Nephrol Dial Transplant 2003; 18: 2118-21.
37. Sorenson. Double Lumen Cannula. United States Patent 1978; 4, 099: 528.
38. Chuang YC, Chen JB, Yang LC, et al. Significance of platelet activation in vascular access survival of hemodialysis patients. Nephrol Dial Transplant 2003; 18: 947-54.
39. Molino D, De Santo NG, Marotta R, et al. Plasma levels of plasminogen activator inhibitor type 1, factor VIII, prothrombin activation fragment 1+2, anticardiolipin, and antiprothrombin antibodies are risk factors for thrombosis in hemodialysis patients. Sem Nephrol 2004; 24: 495-501.
40. Gradzki R, Dhingra RK, Port FK, et al. Use of ACE inhibitors with prolonged survival of arteriovenous grafts. Am J Kidney Dis 2001; 38: 1240-4.
41. Schmitz PG, McCloud LK, Reikes CL, et al. Prophylaxis of hemodialysis graft thrombosis with fish oil: Double-blind, randomized, prospective trial. J Am Soc Nephrol 2002; 13: 184-90.
42. Kaufman JS, O'Conner TZ, Zhang JH, et al. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol 2003; 14: 2313-121.
43. Manns BJ, Burgess ED, Parsons HG, et al. Hyperhomocysteinemia, anticardiolipin antibody status, and risk for vascular access thrombosis in hemodialysis patients. Kidney Int 1999; 55: 315-20.
44. Kaufman JS. Homocysteine and cardiovascular outcomes in kidney disease. Neph Rounds 2004; 2: 1-6.
45. Shemin D, Lapane KL, Bausserman L, et al. Plasma total homocysteine and hemodialysis thrombosis: A prospective study. J Am Soc Nephrol 1999; 10: 1095-9.
46. Sagripanti A, Cupisti A Baicchi U, et al. Plasma parameters of the prothrombotic state in chronic uremia. Nephron 1993; 63: 273-8.
47. Maruyama H, Geyjo F, Hanano M, et al. Acquired type 2 protein C deficiency in a long-term hemodialysis patient. Nephron 1994; 66: 348-50.
48. Casserly LF, Reddy SM, Dember LM. Venous thromboembolism in end-stage renal disease. Am J Kidney Dis 2000; 36: 405-11.
49. Nampoory MR, Das KC, Johny KV, et al. Hypercoagualability, a serious problem in patients with ESRD on maintenance hemodialysis, and its correction after kidney transplant. Am J Kidney Dis 2003; 42: 797-805.
50. Foley RN, Parfrey PS, Harnett JD, et al. Hypoalbuminemia, cardiac morbidity and mortality in end-stage renal disease. J Am Soc Nephrol 1996; 7: 728-36.
51. Mendes RR, Farber MA, Marston WA, et al. Prediction of wrist arteriovenous fistula maturation with preoperative vein mapping with ultrasonography. J Vasc Surg 2002; 36: 460-3.
52. Dixon BS, Novak L, Fangman J. Hemodialysis vascualr access survival: Upper-arm native arteriovenous fistula. Am J Kidney Dis 2002; 39: 92-101.
53. Hossny A. Brachiobasilic arteriovenous fistula: Different surgical techniques and their effects on fistula patency and dialysis-related complications. J Vasc Surg 2003; 37: 821-6.
54. Patel ST, Hughes J, Mills JL. Failure of arteriovenous fistula maturation: An unintended consequence of exceeding dialysis outcomes quality initiative guidelines for hemodialysis access. J Vasc Surg 2003; 38: 439-45.
55. Alexander J, Hood D, Rowe V, et al. Does surgical intervention significantly prolong the patency of failed angioaccess grafts previously treated with percutaneous techniques? Ann Vasc Surg 2002; 16: 197-200.
56. van der Linden J, Smits JH, Assink JH, et al. Short-and long-term functional effects of percutaneous transluminal angioplasty in hemodialysis vascular access. J Am Soc Nephrol 2002; 13: 715-20.
57. Garland JS, Moist LM, Lindsay RM. Are hemodialysis access flow measurements by ultrasound dilution the standard of care for access surveillance? Adv Ren Replace Ther 2002; 9: 91-8.
58. Schwartz C, Mitterbauer C, Boczula M et al. Flow monitoring: performance characteristics of ultrasound dilution versus color Doppler ultrasound compared with fistulography. Am J Kidney Dis 2003; 42: 539-45.
59. Tessitore N, Bedogna V, Gammaro L, et al. Diagnostic accuracy of ultrasound dilution access blood flow measurements in detecting stenosis and predicting thrombosis in native forearem ateriovenous fistulae for hemodialysis. Am J Kidney Dis 2003; 42: 331-41.
60. Arbab-Zadeh A, Mehta RL, Zeigler TW, et al. Hemodialysis access assessment with intravascular ultrasound. Am J Kidney Dis 2002; 39: 813-23.
61. Paulson WD. Access monitoring does not really improve outcomes. Blood Purif 2005; 23: 50-6.
62. Pisoni RL, Young EW, Dykstra DM, et al. Vascular access use in Europe and the United States: Results from DOPPS. Kidney Int 2002; 61: 305-16.
63. Abularrage CJ, Sidway AN, Weisswasser JM, et al. Medical factors affecting patency of arteriovenous access. Semin Vasc Surg 2004; 17: 25-31.